Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Pacira BioSciences's price to book ratio was 2.2× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.8× to 4.7×, with a median of 1.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | +0.6 |
| 2025 | Dec 31, 2025 | 1.5× | +0.4 |
| 2024 | Dec 31, 2024 | 1.2× | −0.7 |
| 2023 | Dec 29, 2023 | 1.9× | −0.4 |
| 2022 | Dec 30, 2022 | 2.3× | −1.4 |
| 2021 | Dec 31, 2021 | 3.7× | −0.7 |
| 2020 | Dec 31, 2020 | 4.4× | −1.0 |
| 2019 | Dec 31, 2019 | 5.5× | −0.4 |
| 2018 | Dec 31, 2018 | 5.9× | −1.1 |
| 2017 | Dec 29, 2017 | 7.0× | +1.4 |
| 2016 | Dec 30, 2016 | 5.6× | −7.9 |
| 2015 | Dec 31, 2015 | 13.5× | −7.1 |
| 2014 | Dec 31, 2014 | 20.6× | −18.6 |
| 2013 | Dec 31, 2013 | 39.2× | +32.2 |
| 2012 | Dec 31, 2012 | 7.1× | −3.7 |
| 2011 | Dec 30, 2011 | 10.7× | – |
See a number that looks wrong?